Cost-effectiveness of M. tuberculosis specific Interferon-gamma release assay testing for the treatment of latent tuberculosis infection in Switzerland

Pneumologie ◽  
2007 ◽  
Vol 61 (S 1) ◽  
Author(s):  
R Diel ◽  
P Wrighton-Smith ◽  
J Zellweger
Keyword(s):  
Cost Effectiveness ◽  
Interferon Gamma ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Interferon Gamma Release Assay ◽  
Release Assay

scholarly journals Interferon Gamma Release Assay for Identifying Latent Tuberculosis Infection in People With Bacillus Calmette-Guérin Vaccination

2021 ◽  
Vol 1 (5) ◽  
Author(s):  
Kendra Brett ◽  
Melissa Severn
Keyword(s):  
Interferon Gamma ◽  
Latent Tuberculosis Infection ◽  
Randomized Study ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Interferon Gamma Release Assay ◽  
Bacillus Calmette Guerin ◽  
Release Assay ◽  
Tuberculosis Therapy ◽  
Evidence Based Guidelines

In people who have been vaccinated with Bacillus Calmette-Guérin, the interferon gamma release assay appears to be related to fewer diagnoses for latent tuberculosis infection, fewer prescriptions of preventive tuberculosis therapy, and no difference in the number of active TB cases compared to the tuberculin skin test (findings based on 1 [non-randomized study] of low quality). No evidence-based guidelines were found regarding the identification of latent tuberculosis infection in people with previous Bacillus Calmette-Guérin vaccination.

Sign in / Sign up

Export Citation Format

Share Document